Localisation
Cytoplasmic and nucleus (Brown et al., 2006) .
Function
Regulation of transcription as a lysine methyltransferase for histone 3, lysine 36 (H3K36) and inhibition of p53's transactivation activity as a lysine methyltransferase for lysine 370 (K370) of p53 through the SET domain (Brown et al., 2006; Huang et al., 2006) . Possibly promotion of cell proliferation and/or differentiation through its overexpression/activationinduced inhibition of p53's transactivation activity. Methylation of retinoblastoma (RB) tumor suppressor at lysine 860, that is regulated during cell cycle progression, cellular differentiation ,and in response to DNA damage (Saddic et al., 2010) . RB monomethylation at lysine 860 provides a direct binding site for the transcription repressor L3MBTL1. Through interaction with HSP90alpha, SMYD2 histone methyltransferase activity and specificity for histone H3 at lysine 4 (H3K4) are enhanced in vitro (AbuFarha et al., 2008) . SMYD2 gain of function is correlated with the upregulation of 37 and down regulation of 4 genes, the majority of which are involved in the cell cycle, chromatin remodelling, and transcriptional regulation (Abu-Farha et al., 2008) .
Homology
Xenopus laevis, Zebrafish, Chicken, Gray short-tailed opossum, Mouse, Rat, Rabbit, Pig, Horse, Cattle, Dog, White-tufted-ear marmoset, Rhesus monkey, Sumatran orangutan, Chimpanzee.
SMYD2 (SET and MYND domain containing 2)
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Mutations Note Not found.
Implicated in

Esophageal squamous cell carcinoma (ESCC)
Note Frequent overexpression of SMYD2 mRNA and protein was observed in KYSE150 cells with remarkable amplification at 1q32-q41.1 and other ESCC cell lines (11/43 lines, 25.6%). Overexpression of SMYD2 protein was frequently detected in primary tumor samples of ESCC (117/153 cases, 76.5%) as well and significantly correlated with gender, venous invasion, the pT category in the tumor-lymph nodemetastasis classification and status of recurrence. Patients with SMYD2-overexpressing tumors had a worse overall rate of survival than those with nonexpressing tumors. Knockdown of SMYD2 expression inhibited and ectopic overexpression of SMYD2 promoted the proliferation of ESCC cells in a TP53 mutation-independent but SMYD2 expression dependent manner (Komatsu et al., 2009 ).
Thyroid carcinoma and benign thyroid nodule
Note Using differential display-polymerase chain reaction method, the gene expression differences between benign thyroid nodules (BTNs) and follicular and classic variants of papillary thyroid carcinoma (PTC) were evaluated in a group of 42 patients (15 BTNs, 14 follicular variant of PTC and 13 classic variant of PTC). SMYD2 had lower expression in both carcinoma groups than in BTNs (Igci et al., 2011) .
Breast cancer
Note
Expression of a group of three genes (MTSS1, RPL37, and SMYD2) evaluated by real-time PCR was shown to be a potential candidate to predict response to neoadjuvant chemotherapy (4 cycles of doxorubicin and cyclophosphamide) in breast cancer patients (Barros Filho et al., 2010) .
